R2810-ONC-1540
25 Nov 2020
Trial Summary
Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
Acronym:
R2810-ONC-1540
ACTRN/NCT /ethics:
NCT02760498
Scientific title:
A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients With Advanced Cutaneous Squamous Cell Carcinoma
Sponsor / Cooperative group:
Regeneron
Trial & Patient Characteristics
| Cancer Type | Melanoma & other skin |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18 years and older |
| Sex | Both |
| Tumour Stream | Cutaneous squamous cell carcinoma |
| Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
| Anticipated Start Date | - |
| Anticipated End Date | - |
Participating Hospitals
| Hospital | Ashford Cancer Centre Research |
|---|---|
| Clinical Trial Coordinator | Sue Yeend |
| syeend@adelaidecancercentre.com.au | |
| Phone | 08 8292 2240 |
| Principal Investigator | Dr Brian Stein |
| Recruitment Status | Recruiting |